{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:00:34Z","timestamp":1781586034760,"version":"3.54.5"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1201","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Study Purpose<\/jats:title>\n                  <jats:p>This study assesses the efficacy and safety of direct oral anticoagulants (DOACs) compared to traditional anticoagulants in managing portal vein thrombosis (PVT), aiming to address critical gaps in both research and clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design<\/jats:title>\n                  <jats:p>We conducted a retrospective analysis at Rochester General Hospital from January 2011 to December 2023, involving 275 cirrhotic patients with PVT. The inclusion criteria included confirmed non-neoplastic PVT by imaging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analysis of 275 cirrhotic patients with PVT revealed no significant differences in age and gender between those treated with anticoagulants and those untreated. The mortality rate was significantly lower in the treated group (37.7%) compared to the untreated group (51.7%; P\u2009=\u20090.029). Gastrointestinal bleeding was slightly more prevalent in the treated group (60.7%) than in the untreated group (58.1%; P\u2009=\u20090.690), though not statistically significant. A significant reduction in intracranial hemorrhage was observed in the treated group (2.5% vs. 8.5% in the untreated group; P\u2009=\u20090.038). In a subgroup analysis comparing the outcomes and side effects of DOACs, Warfarin, and low molecular weight heparins (LMWH) in treated PVT patients, the DOAC group showed improved survival rates compared to traditional [vitamin K antagonists (VKA)\/LMWH] treatment, a log-rank test indicated significant survival improvement (chi2 (1)\u2009=\u20098.27, P\u2009=\u20090.0040). DOACs demonstrated comparable mortality rates to VKAs (34.2% vs. 34.5%, P\u2009=\u20090.979) and a significant survival benefit over LMWH (33.3% vs. 60.0%, P\u2009=\u20090.030).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DOAC in treating PVT among patients with liver cirrhosis, demonstrating better significant survival rate when compared to traditional anticoagulation.<\/jats:p>\n                  <jats:p>Key message What is already known on this topic\u00a0 Portal vein thrombosis (PVT) is significantly more prevalent in patients with liver cirrhosis compared to the general population, posing substantial management challenges. Previous studies have primarily focused on small cohorts and retrospective data, underscoring the need for robust, large-scale analyses to validate the efficacy and safety of direct oral anticoagulants (DOACs) versus traditional therapies. What this study adds\u00a0 This study provides concrete evidence from a large cohort that DOACs not only offer a survival benefit over traditional anticoagulation therapies like Warfarin and LMWH in cirrhotic patients with PVT but also maintain comparable safety profiles. These findings bridge significant gaps in current research by comparing the outcomes of modern versus traditional anticoagulant approaches in a real-world setting. How this study might affect research, practice, or policy\u00a0 The results advocate for the inclusion of DOACs in clinical guidelines for managing PVT in cirrhosis, potentially shifting clinical practice toward these agents. Furthermore, the detailed comparison and subgroup analyses provide a strong foundation for future randomized controlled trials, which could further refine anticoagulation strategies in this high-risk population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/postmj\/qgaf062","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:10:24Z","timestamp":1745914224000},"page":"1166-1172","source":"Crossref","is-referenced-by-count":6,"title":["Anticoagulation outcomes in cirrhotic patients with portal vein thrombosis: a tertiary center study"],"prefix":"10.1093","volume":"101","author":[{"given":"Chengu","family":"Niu","sequence":"first","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of psychiatry, Rainier Springs Behavioral Health Hospital , 2805 NE 129th St, Vancouver, WA 98686 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoate-Domench","family":"Daniel-Jose","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teibel","family":"Zachary","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orakzai","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Shah","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltaher","family":"Basant","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devam","family":"Maity","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firoze A","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagesh","family":"Jadhav","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, Rochester General Hospital , Rochester, NY 14621 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick I","family":"Okolo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Carillion Clinic , 3 Riverside Cir SW, Roanoke, VA 24016, \u00a0","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daglilar","family":"Ebubekir","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Charleston Area Medical Center\/CAMC Institute For Academic Medicine Program , 2930 Chesterfield Ave, Charleston, WV 25304 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2025102100061672400_ref1","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/jth.15239","article-title":"The concept of rebalanced hemostasis in patients with liver disease: communication from the ISTH SSC working group on hemostatic management of patients with liver disease","volume":"19","author":"Lisman","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025102100061672400_ref2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/HEP.0000000000000349","article-title":"The evolving knowledge on primary hemostasis in patients with cirrhosis: a comprehensive review","volume":"79","author":"Zanetto","year":"2024","journal-title":"Hepatology"},{"key":"2025102100061672400_ref3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrgastro.2014.36","article-title":"Management of portal vein thrombosis in liver cirrhosis","volume":"11","author":"Qi","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025102100061672400_ref4","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata","year":"2019","journal-title":"Gastroenterology"},{"key":"2025102100061672400_ref5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1055\/s-0040-1714205","article-title":"Incidence of bleeding and thrombosis in patients with liver disease","volume":"46","author":"Roberts","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"2025102100061672400_ref6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jceh.2021.11.003","article-title":"Portal vein thrombosis in cirrhosis","volume":"12","author":"Shukla","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"2025102100061672400_ref7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejim.2022.05.032","article-title":"Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"104","author":"Pan","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2025102100061672400_ref8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC\u2013associated bleeding, hemostatic strategies, and thrombin generation assays-a review of the literature","volume":"21","author":"Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2025102100061672400_ref9","doi-asserted-by":"publisher","first-page":"757087","DOI":"10.3389\/fcvm.2021.757087","article-title":"Diagnostic accuracy of the HAS-BLED bleeding score in VKA-or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2025102100061672400_ref10","doi-asserted-by":"publisher","first-page":"e2240145","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025102100061672400_ref11","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.jhepr.2024.101116","article-title":"Direct oral anticoagulants in liver cirrhosis: rationale and current evidence","volume":"6","author":"Portela","year":"2024","journal-title":"JHEP Rep"},{"key":"2025102100061672400_ref12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"key":"2025102100061672400_ref13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jceh.2022.12.016","article-title":"Anticoagulation for the treatment of portal vein thrombosis in cirrhosis: a systematic review and meta-analysis of comparative studies","volume":"13","author":"Yao","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"2025102100061672400_ref14","doi-asserted-by":"publisher","first-page":"10760296221104797","DOI":"10.1177\/10760296221104797","article-title":"The efficacy and safety of anticoagulants in the treatment of cirrhotic portal vein thrombosis: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025102100061672400_ref15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/qjmed\/hcz127","article-title":"Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis","volume":"112","author":"Lapumnuaypol","year":"2019","journal-title":"QJM"},{"key":"2025102100061672400_ref16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40256-021-00482-w","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis","volume":"22","author":"Lee","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025102100061672400_ref17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol Res"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/101\/1201\/1166\/63027360\/qgaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/101\/1201\/1166\/63027360\/qgaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:06:25Z","timestamp":1761019585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/101\/1201\/1166\/8121702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":17,"journal-issue":{"issue":"1201","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,10,18]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgaf062","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,4,29]]}}}